Study to Evaluate the Safety and Tolerability of Avelumab in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies

Inclusion Criteria:

1. For all arms except Arm G, subjects must be refractory to, or intolerant of,
established therapy known to provide clinical benefit for their conditions, or where
subjects refuse existing therapies. For Arm G, subjects must have newly histologically
or cytologically confirmed diagnosis of locally advanced cervical cancer confined to
the pelvis only.

2. Subjects must have measurable disease (RECIST v1.1) or patients may have bone
metastatic disease evaluable by Prostate Cancer Working Group 2 (PCWG2) for subjects
with metastatic castration-resistant prostate cancer (CRPC) or according to tumor
evaluation criteria best suitable and accepted for the tumor type evaluated.

3. Age >/= 18 years.

4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

5. Adequate hematologic function defined as: Platelets >/= 100 x 10^9/L; Hemoglobin >/= 9
g/dL; Absolute Neutrophil Count (ANC) >/=1.5 x 10^9/L; White Blood Cell (WBC) >/= 3 x
10^9/L; Absolute Lymphocyte Count (ALC) >/= 0.8 x 10^9/L. Subjects must be transfusion
independent (ie, no blood product transfusions for a period of at least 14 days prior
to screening).

6. Adequate liver function defined as: Alanine transaminase (ALT) limit (ULN) ( Aspartate aminotransferase (AST) documented metastatic disease to the liver); Alkaline phosphatase < 4 x ULN; Total
Bilirubin [hereditary indirect hyperbilirubinemia] who must have a total bilirubin of ULN); Albumin >/=3 g/dL.

7. Renal function defined serum creatinine estimated creatinine clearance >/=30 ml/min as calculated using the Cockcroft-Gault
formula. For Arm G, subjects must have an estimated creatinine clearance >/= 50
ml/min.

8. Subject has recovered to Grade Terminology Criteria for Adverse Events, Version 4.03 (NCI-CTCAE v4.03) from the
effects of recent surgery, radiotherapy, chemotherapy, hormonal therapy, or other
targeted therapies, with the exception of alopecia. The exceptions for such effects
are allowed lab values of
9. Life expectancy of at least 12 weeks.

10. Negative serum pregnancy test in women of childbearing potential within 7 days of
first dose of treatment and patients of child-bearing potential must agree to use
effective contraception during and after 90 days post dose. A woman of childbearing
potential is defined as a premenopausal female capable of becoming pregnant. This
includes women on oral, injectable or mechanical contraception; women who are single
and women whose male sexual partners have been vasectomized or whose male sexual
partners have received or are utilizing mechanical contraceptive devices.

11. Subjects must have biopsiable disease. For Arms A, B, and C, subjects must have at
least two lesions amenable to biopsy and response evaluation. For Arms D, E, F, and G,
subjects must have at least three lesions amenable to biopsy, response evaluation, and
radiation. Tumor lesions used for biopsy should not be lesions used as RECIST target
lesions.

12. Subjects must give informed consent according to the rules and regulations of the
individual participating sites.

Exclusion Criteria:

1. Subjects with primary central nervous system (CNS) tumor or CNS tumor involvement.
However, subjects with metastatic CNS tumors may participate in this study if the
subject is: >4 weeks from prior therapy completion (including radiation and/or
surgery); Clinically stable with respect to the CNS tumor at the time of study entry;
Not receiving steroid therapy in treating CNS tumor or CNS tumor involvement; Not
receiving anti-convulsive medications (that were started for brain metastases).

2. Major surgery, radiation therapy or systemic anti-cancer therapy within 4 weeks of
study drug administration (6 weeks for mitomycin C or nitrosoureas). Palliative
radiotherapy to a limited field is allowed after consultation with the medical monitor
at any time during study participation, including during screening, unless it's
clearly indicative of disease progression. For Arm G, subjects who require extended
field radiation therapy will be excluded.

3. Subjects with prior anti-PD-1, anti-PD-L1 treatment. For Arms A and D, subjects may
not have had prior 4-1BB treatment. For Arms B and E, subjects may not have had prior
OX40 treatment. For Arms C and F, subjects may not have had prior 4-1BB or OX40
treatment.

4. Diagnosis or recurrence of invasive cancer other than the present cancer within 3
years (except basal or squamous cell carcinoma of the skin that has been definitively
treated).

5. Clinically significant (i.e., active) cardiovascular disease: cerebral vascular
accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months
prior to enrollment), unstable angina, congestive heart failure (>/= New York Heart
Association Classification Class II), or serious cardiac arrhythmia requiring
medication.

6. Active infection requiring systemic therapy.

7. Treatment with an investigational anti-cancer study drug within 4 weeks prior to study
drug administration date.

8. Concurrent therapy with approved or investigational anticancer therapeutics.

9. Known prior severe hypersensitivity to investigational product(s) or any component in
its formulations, including known severe hypersensitivity reactions to monoclonal
antibodies (NCI CTCAE v4.03 Grade >/= 3).

10. If in Arm G, significant allergic reaction to cisplatin.

11. Current use of immunosuppressive medication, EXCEPT for the following: a. intranasal,
inhaled, topical steroids, or local steroid injection (e.g., intra-articular
injection); b. Systemic corticosteroids at physiologic doses prednisone or equivalent; c. Steroids as premedication for hypersensitivity reactions
(e.g., CT scan premedication).

12. Active autoimmune disease that might deteriorate when receiving an immuno-stimulatory
agent. Patients with diabetes type I, vitiligo, psoriasis, or hypo- or hyperthyroid
diseases not requiring immunosuppressive treatment are eligible.

13. Prior organ transplantation including allogenic stem-cell transplantation.

14. Known history of testing positive for HIV or known acquired immunodeficiency syndrome.

15. Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening (positive
HBV surface antigen or HCV RNA if anti-HCV antibody screening test positive).

16. Vaccination (live attenuated virus) within 4 weeks of the first dose of avelumab and
while on trials is prohibited except for administration of inactivated vaccines.

17. Persisting toxicity related to prior therapy (NCI CTCAE v. 4.03 Grade > 1); however,
alopecia, sensory neuropathy Grade safety risk based on investigator's judgment are acceptable.

18. Other severe acute or chronic medical conditions including colitis, inflammatory bowel
disease, pneumonitis, pulmonary fibrosis or psychiatric conditions including recent
(within the past year) or active suicidal ideation or behavior; or laboratory
abnormalities that may increase the risk associated with study participation or study
treatment administration or may interfere with the interpretation of study results
and, in the judgment of the investigator, would make the patient inappropriate for
entry into this study.

19. Medical, psychological or social conditions that may interfere with the patient's
participation in the study or evaluation of the study results.

20. Pregnancy or lactation.

21. Men whose partner is a woman of child-bearing potential, (i.e. biologically able to
conceive), and who is not employing two forms of highly effective contraception.
Highly effective contraception (e.g. male condom with spermicide, diaphragm with
spermicide, intra-uterine device) must be used by both sexes during the study and must
be continued for 90 days after the end of study treatment. Women of child-bearing
potential is defined as sexually mature women who are not surgically sterile or who
have not been naturally postmenopausal for at least 12 consecutive months (e.g., who
has had menses any time in the preceding 12 consecutive months).

22. A diagnosis of active scleroderma, lupus, or other rheumatologic disease which in the
opinion of the treating radiation oncologist precludes safe radiation therapy.

23. Has had prior radiation therapy within the past 3 months where the high dose area of
the prior radiation would overlap with the high dose area of the intended radiation
based on the judgement of the treatment oncologist.

24. For Arm G, patients with disease beyond the pelvis, including but not limited to the
para-aortic nodes as determined by PET/CT will be excluded.